Home Cart 0 Sign in  

[ CAS No. 956136-85-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 956136-85-9
Chemical Structure| 956136-85-9
Structure of 956136-85-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 956136-85-9 ]

Related Doc. of [ 956136-85-9 ]

Alternatived Products of [ 956136-85-9 ]

Product Details of [ 956136-85-9 ]

CAS No. :956136-85-9 MDL No. :MFCD16652353
Formula : C22H34BNO4 Boiling Point : -
Linear Structure Formula :- InChI Key :ZDJWODLFNSRSNA-UHFFFAOYSA-N
M.W : 387.32 Pubchem ID :53629760
Synonyms :

Calculated chemistry of [ 956136-85-9 ]

Physicochemical Properties

Num. heavy atoms : 28
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.68
Num. rotatable bonds : 5
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 117.56
TPSA : 48.0 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -5.59 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 4.33
Log Po/w (WLOGP) : 3.72
Log Po/w (MLOGP) : 2.73
Log Po/w (SILICOS-IT) : 2.84
Consensus Log Po/w : 2.73

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.8
Solubility : 0.00617 mg/ml ; 0.0000159 mol/l
Class : Moderately soluble
Log S (Ali) : -5.05
Solubility : 0.00343 mg/ml ; 0.00000886 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.32
Solubility : 0.00185 mg/ml ; 0.00000476 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.54

Safety of [ 956136-85-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 956136-85-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 956136-85-9 ]
  • Downstream synthetic route of [ 956136-85-9 ]

[ 956136-85-9 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 769944-78-7 ]
  • [ 73183-34-3 ]
  • [ 956136-85-9 ]
YieldReaction ConditionsOperation in experiment
93% With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate In 1,4-dioxane at 100℃; Inert atmosphere; Sealed tube In a pressure tube a solution of tert-butyl 4-(4-bromophenyl)piperidine-1-carboxylate (1363 mg, 4.006 mmol) in dioxane was treated with bis(pinacolato)diboron (1526 mg, 6.009 mmol), KOAc (1179 mg, 12.02 mmol), and PdC12(dppf).DCM (327.1 mg, 0.4006 mmol). The mixture was sparged with nitrogen for 1 mm and then sealed and heated at 100 °C overnight. After cooling to ambient temperature, the reaction mixture was diluted with a mixture of EtOAc (75 mL)/water (50 mL)/ brine (25 mL), and the resulting emulsion was filtered through Celite® and rinsed with EtOAc. The biphasic filtrate was separated and the organic phase was washed with brine and then dried (MgSO4), filtered and concentrated in vacuo. The crude residue was purified by silica chromatography (0-50percent EtOAc/hexanes) to afford the title compound (1437 mg, 93percent yield). ‘H NMR (CDC13) 7.76 (d, 2H), 7.22 (m, 2H), 4.24 (d, 2H), 2.79 (dt, 2H), 2.65 (tt, 1H), 1.81 (m, 2H), 1.63 (dq, 2H), 1.48 (s, 9H), 1.33 (s, 12H).
86% With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate In 1,2-dimethoxyethane at 80℃; Inert atmosphere A mixture of tert-butyl 4- (4-bromophenyl) piperidine-1-carboxylate (510 mg, 1.499 mmol) , 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (761 mg, 3 mmol) and KOAc (441 mg, 4.5 mmol) in DME (20 ml) was degassed with N2 and PdCl2 (dppf) -CH2Cl2 (122 mg, 0.15 mmol) was added. The resulting mixture was degassed with N2 again and was heated to 80 overnight. After cooling to rt, the mixture was added with 10mL of NH4Cl (aq) , and extracted with EtOAc (20mL × 2) . The combined organic phase was washed with brine (20mL) , dried over Na2SO4 (anhydrous) , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (EA/Hexane 0: 100-1: 5) to give the title compound (500 mg , 86) . 1H NMR (400 MHz, CDCl3) δ ppm 1.27 (s, 9H) , 1.34 (s, 12H) , 1.57 -1.72 (m, 2H) , 1.82 (br d, J13.05 Hz, 2H) , 2.66 (br s, 1 H) , 2.80 (br t, J12.05 Hz, 2H) , 4.25 (br d, J12.80 Hz, 2H) , 7.11 -7.42 (m, 2H) , 7.77 (d, J8.03 Hz, 2H) . LC-MS: [M+H-100] + 288.2.
3.81 g With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In dimethyl sulfoxide at 80℃; Inert atmosphere A solution of tert-butyl 4-(4-bromophenyl)piperidine-1-carboxylate (3.38 g, 11.25 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (4.57 g, 18 mmol), Pd(dppf)Cl2 (2.47 g, 3.38 mmol) and KOAc (3.32 g, 33.75 mmol) in 60 mL of DMSO, under N2, was stirred at 80° C. overnight.
The volatiles were removed in vacuo, and the residue was purified by chromatography with PE/EA (40:1˜1:1) to give 3.81 g of title compound.
Reference: [1] Patent: WO2017/11776, 2017, A1, . Location in patent: Paragraph 00701
[2] Patent: WO2017/114497, 2017, A1, . Location in patent: Page/Page column 339
[3] Patent: WO2018/59549, 2018, A1, . Location in patent: Page/Page column 293
[4] Patent: WO2007/126957, 2007, A2, . Location in patent: Page/Page column 101
[5] Patent: WO2009/7390, 2009, A2, . Location in patent: Page/Page column 96
[6] Patent: WO2013/130370, 2013, A2, . Location in patent: Page/Page column 39; 40
[7] Patent: US2014/121200, 2014, A1, . Location in patent: Paragraph 0329; 0331
  • 2
  • [ 769944-78-7 ]
  • [ 25015-63-8 ]
  • [ 956136-85-9 ]
YieldReaction ConditionsOperation in experiment
59.4% With triethylamine In 1,4-dioxane at 110℃; for 1.5 h; Inert atmosphere Step A: Preparation of tert-butyl 4-(4-(4A5,5-tetramethyl-1 ,2-dioxaborolan-2-yl)phenyl)piperidine- 1 -carboxylate : To a solution of tert-butyl 4-(4-bromophenyl) piperidine-l-carboxylate (13.5 g, 39.7 mmol) in dioxane (40 mL) was added 4,4,5,5- tetramethyl-l,3,2-dioxaborolane (8.64 mL, 59.5 mmol) and triethylamine (16.6 mL, 119 mmol). The solution was purged with argon for 5 minutes. Dichlorobis(acetonitrile) palladium (0.309 g, 1.19 mmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (1.95 g, 4.76 mmol) were then added, and the reaction mixture was again purged with argon for 5 minutes. The reaction mixture was then sealed and heated at 110 °C for 90 minutes. The reaction mixture was cooled to ambient temperature and filtered through a glass fiber filter paper. The filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography, eluting with 5-10percent EtOAc in hexanes to afford tert-butyl 4-(4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)piperidine-l-carboxylate (9.13 g, 23.6 mmol, 59.4percent yield) as a solid. MS (apci) m/z = 288.3 (M+H-Boc).
Reference: [1] Patent: WO2011/130146, 2011, A1, . Location in patent: Page/Page column 148
  • 3
  • [ 273727-44-9 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/112441, 2015, A1,
[2] Patent: WO2015/88045, 2015, A1,
[3] Patent: US2017/8885, 2017, A1,
[4] Patent: WO2017/38909, 2017, A1,
[5] Patent: WO2016/206101, 2016, A1,
[6] Patent: US2016/333021, 2016, A1,
  • 4
  • [ 106-37-6 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/112441, 2015, A1,
[2] Patent: WO2016/206101, 2016, A1,
[3] Patent: US2016/333021, 2016, A1,
  • 5
  • [ 79099-07-3 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/112441, 2015, A1,
[2] Patent: WO2016/206101, 2016, A1,
[3] Patent: US2016/333021, 2016, A1,
  • 6
  • [ 163209-96-9 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/112441, 2015, A1,
[2] Patent: WO2016/206101, 2016, A1,
[3] Patent: US2016/333021, 2016, A1,
  • 7
  • [ 91347-99-8 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/112441, 2015, A1,
[2] Patent: WO2016/206101, 2016, A1,
[3] Patent: US2016/333021, 2016, A1,
  • 8
  • [ 589-87-7 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/88045, 2015, A1,
[2] Patent: US2017/8885, 2017, A1,
[3] Patent: WO2017/38909, 2017, A1,
  • 9
  • [ 375853-82-0 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: WO2015/88045, 2015, A1,
[2] Patent: US2017/8885, 2017, A1,
[3] Patent: WO2017/38909, 2017, A1,
  • 10
  • [ 80980-89-8 ]
  • [ 24424-99-5 ]
  • [ 956136-85-9 ]
Reference: [1] Patent: US2014/121200, 2014, A1,
[2] Patent: WO2017/11776, 2017, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 956136-85-9 ]

Organoboron

Chemical Structure| 1035235-26-7

[ 1035235-26-7 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

Similarity: 0.89

Chemical Structure| 905273-91-8

[ 905273-91-8 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate

Similarity: 0.88

Chemical Structure| 2126812-29-9

[ 2126812-29-9 ]

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate

Similarity: 0.88

Chemical Structure| 1032528-06-5

[ 1032528-06-5 ]

tert-Butyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)carbamate

Similarity: 0.87

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.86

Aryls

Chemical Structure| 2126812-29-9

[ 2126812-29-9 ]

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate

Similarity: 0.88

Chemical Structure| 1032528-06-5

[ 1032528-06-5 ]

tert-Butyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)carbamate

Similarity: 0.87

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.86

Chemical Structure| 889865-34-3

[ 889865-34-3 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-carboxylate

Similarity: 0.85

Chemical Structure| 1912446-60-6

[ 1912446-60-6 ]

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate

Similarity: 0.85

Amides

Chemical Structure| 1035235-26-7

[ 1035235-26-7 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

Similarity: 0.89

Chemical Structure| 905273-91-8

[ 905273-91-8 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate

Similarity: 0.88

Chemical Structure| 2126812-29-9

[ 2126812-29-9 ]

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate

Similarity: 0.88

Chemical Structure| 1032528-06-5

[ 1032528-06-5 ]

tert-Butyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)carbamate

Similarity: 0.87

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.86

Related Parent Nucleus of
[ 956136-85-9 ]

Piperidines

Chemical Structure| 889865-34-3

[ 889865-34-3 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-carboxylate

Similarity: 0.85

Chemical Structure| 1224449-13-1

[ 1224449-13-1 ]

(4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methyl)phenyl)boronic acid

Similarity: 0.77

Chemical Structure| 1048970-17-7

[ 1048970-17-7 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylate

Similarity: 0.71

Chemical Structure| 1000931-04-3

[ 1000931-04-3 ]

1-Boc-3-Hydroxy-4-phenylpiperidine

Similarity: 0.66

Chemical Structure| 877399-74-1

[ 877399-74-1 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

Similarity: 0.62